A standardization method to adjust for the effect of patient selection in phase II clinical trials.
about
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Phase II designs for anticancer botanicals and supplements.
P2860
A standardization method to adjust for the effect of patient selection in phase II clinical trials.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A standardization method to ad ...... n in phase II clinical trials.
@en
A standardization method to ad ...... n in phase II clinical trials.
@nl
type
label
A standardization method to ad ...... n in phase II clinical trials.
@en
A standardization method to ad ...... n in phase II clinical trials.
@nl
prefLabel
A standardization method to ad ...... n in phase II clinical trials.
@en
A standardization method to ad ...... n in phase II clinical trials.
@nl
P2093
P2860
P356
P1476
A standardization method to ad ...... n in phase II clinical trials.
@en
P2093
Mazumdar M
Panageas KS
P2860
P304
P356
10.1002/SIM.706
P407
P577
2001-03-01T00:00:00Z